Abstract 2152P
Background
The Gustave Roussy Immune Score (GRIm-Score) was first used in 2017 as a prognostic index. Since the immune pathways in the pathogenesis of HCC has been demonstrated, it was aimed to examine the relationship between GRIm-score and patient survival, treatment side effects and the frequency of hospitalization in HCC patients.
Methods
In between 2010-2021, 108 patients with metastatic or unresectable HCC in our center were screened. Patients receiving sorafenib therapy and ecog 0-1 were included. Clinicopathological data, GRIm scores prior to the sorafenib treatment, previous treatment modalities of patients, hematological side effects of sorafenib, and hospitalizations to the oncology inpatient ward, excluding hospitalizations for planned procedure or chemotherapy, were recorded retrospectively. For the GRIM-Score, patients with NLR > 4.8, LDH > upper limit of normal, or albumin < 3.5 g/dL were given 1 point. Patients were divided in two groups according to the GRIM-Score as low and high.
Results
Sixty four patients were included in the study. Median age was 65 and 95.3% of the patients were male. 79.7% of them had chronic hepatitis. Most of the patients (68%) performed previous local ablative therapy. Low GRIM score (0-1) was demonstrated 60.9% of patients, whereas 39.1% of them had high score(2-3). Hematological side effects and/or AST elevation were observed in 32% of the patients. Hematological side effects were seen in 23% of all patients. During the follow-up period, 75.2% of the patients were hospitalized at least once. 72% of hospitalizations were for supportive treatment. The median number of hospitalizations was 1. The median OS was 5 months. The median survival in the low and high GRIm-score group was 8.8 and 2.7 months respectively (p<0.0001). Hospitalization requirement was found to be significantly higher in the high-GRIm score group compared to low GRIm-score group (p: 0.017). There was no significant difference between the presence of side effects and the GRIm-score group (p: 0.664).
Conclusions
The GRIm-score at the beginning of sorafenib therapy can be used as a significant marker both to determine survival and to predict the need for supportive care in metastatic/unresectable HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07